A mechanistic look at sacubitril/valsartan action. Unravelling magician's secrets

The “Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure” (PARADIGM-HF) trial has shaken the medical community with its striking results in terms of reduction of cardiovascular mortality and heart failure (HF) hospitalization among patients with systolic HF treated with the novel angiotensin-receptor/neprilysin inhibitor (ARNI) LCZ696 (also named sacubitril/valsartan), compared with the angiotensin converting enzyme inhibitor (ACEI) enalapril.
Source: International Journal of Cardiology - Category: Cardiology Authors: Tags: Editorial Source Type: research